A rare cause of childhood-onset nephrotic syndrome: lipoprotein glomerulopathy.

Abstract

We report on a 12-year-old female patient with lipoprotein glomerulopathy (LPG) who was proven to be heterozygous for ApoE2 Kyoto (Arg25Cys). Her family members have the same variant but do not have obvious signs of renal function impairment. Six months of treatment with a statin caused significant clinical improvement in the lipid profile, proteinuria, and renal function. Our case suggests that administration of a statin is a potential therapeutic strategy for improving nephrotic syndrome in patients with LPG.

• Authors: Min-Tser Liao, I-Jung Tsai, Hui-Teng Cheng, Wei-Chou Lin, Yen-Wen Chang, Yi-Heng Lin, Yong-Kwei Tsau
• Journal: Clinical nephrology (Clin Nephrol) Vol. 78 Issue 3 Pg. 237-40 (Sep 2012) ISSN: 0301-0430 [Print] Germany
• PMID: 22874113 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Antihypertensive Agents
• Apolipoprotein E2
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• apolipoprotein E2 (Kyoto)
• Enalapril
• Pravastatin
• Methylprednisolone

Topics

• Age of Onset
• Anti-Inflammatory Agents (therapeutic use)
• Antihypertensive Agents (therapeutic use)
• Apolipoprotein E2 (genetics)
• Child
• Enalapril (therapeutic use)
• Female
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Methylprednisolone (therapeutic use)
• Mutation
• Nephrotic Syndrome (drug therapy, genetics)
• Pravastatin (therapeutic use)